For years, gut health has been used liberally across research papers, probiotic marketing campaigns, and patient conversations—often without a consistent clinical definition. Now, a new 2026 consensus statement from the International Scientific Association for Probiotics and Prebiotics (ISAPP), published in Nature Reviews Gastroenterology & Hepatology, attempts to bring much-needed clarity to a term that sits at the intersection of microbiome science, GI physiology, and patient-reported outcomes. For gastroenterologists, the key shift is this: gut health is no longer defined solely by the absence of disease—but by the presence of normal GI function and the absence of symptoms that meaningfully impact…
Author: Abhay Panchal
Medical malpractice continues to be an occupational reality in gastroenterology. In fact, a landmark study by Jena et al. found that most gastroenterologists will face at least one lawsuit over the course of their careers. While many claims never result in financial penalties, the emotional toll, reputational risk, and time burden can be substantial. In GI practice, litigation is most often triggered by missed or delayed diagnoses, endoscopic complications—particularly during ERCP—perforations, and breakdowns in communication. And in today’s fast-paced clinical environment, opportunities to build rapport with patients are becoming increasingly limited. Workflows like open-access endoscopy and reliance on electronic medical…
Artificial intelligence is steadily moving from hype to hands-on utility in endoscopy suites. In this edition of Sharma’s Endoscopy Insights, two recent studies explore how AI could enhance both optical diagnosis and quality measurement during colonoscopy. The first study evaluated computer-aided diagnosis (CADx) in identifying sessile serrated lesions (SSLs)—a known blind spot in colorectal cancer prevention. Endoscopists demonstrated higher diagnostic accuracy when CADx supported optical classification, particularly in distinguishing SSLs from hyperplastic polyps. However, current systems still face limitations in reliably characterizing these lesions, highlighting the need for further refinement. The second study focused on withdrawal time, a key colonoscopy…
Despite the introduction of more specific ICD-10-CM codes for short bowel syndrome (SBS), new real-world U.S. claims data presented at ASPEN 2026 suggest that the majority of eligible patients may still be going uncounted. In an analysis led by Alan Buchman, MD, MSPH, researchers found that only 28% of the expected SBS population was captured using the updated, syndrome-specific codes—raising concerns around widespread undercoding and misclassification in clinical practice. Historically, SBS prevalence estimates have varied significantly due to reliance on broad diagnostic labels such as postoperative malabsorption, which fail to distinguish between patients with minimal resections and those with true…
A new population-based study published in Clinical Gastroenterology and Hepatology evaluated the real-world performance of a smartphone-based fecal immunochemical test (FIT) designed for at-home colorectal cancer (CRC) screening—no lab visit required. Conducted within Germany’s BLITZ screening cohort (2021–2023), the study compared a rapid stool test interpreted via smartphone camera with a conventional laboratory FIT among individuals scheduled for screening colonoscopy. More than half of participants (55%) opted to use the smartphone-based FIT, and 89% viewed it as a useful alternative to traditional lab-based testing. Among users, the digital FIT demonstrated comparable specificity (92%) and similar sensitivity for detecting advanced neoplasms…
The American Gastroenterological Association (AGA) has released updated practice guidance on Barrett’s esophagus (BE) surveillance, marking its first comprehensive update on post-diagnosis monitoring since 2011. Published in Gastroenterology, the guideline introduces eight evidence-based recommendations that shift BE surveillance away from a one-size-fits-all model toward a more individualized, risk-based approach. Notably, BE segment length is now recommended as a key determinant for guiding endoscopic surveillance intervals, while routine surveillance is no longer advised for patients with columnar-lined esophagus measuring less than 1 cm in the absence of dysplasia or visible lesions. The guidance also underscores the importance of reassessing surveillance based…
The gastroenterology workforce is entering a pivotal stretch as an aging physician base collides with rising patient demand, all the while access gaps widen and compensation pressures mount in the background. Here are five trends to keep an eye on: 1. Large geographic access gaps persist across the GI workforce: More than two-thirds of U.S. counties do not have a practicing gastroenterologist, according to a Nov. 14 report from Medicus Healthcare Solutions. The report found that about 7 million people live more than 50 miles from a GI specialist. Workforce constraints are also tightening recruitment, with healthcare organizations taking a…
New data presented at ECCO 2026 suggests that a site-centric, AI-supported research network may significantly improve the speed and consistency of clinical trial execution in inflammatory bowel disease (IBD). Evaluating multiple Phase II and III trials across ulcerative colitis and Crohn’s disease in the U.S. and Europe, Iterative Health’s global site network demonstrated an average patient enrollment rate of 0.34 per site per month—approximately 3.4× higher than published industry benchmarks. Trial activation timelines were also notably shorter, with a median of 74 days from site selection to activation compared to the typical 120–171 days, translating to a potential three-month time…
As most colorectal cancers (CRC) originate from precancerous adenomas, the ability to detect these lesions early remains central to reducing disease burden. A new review highlights the growing promise of blood-based biomarkers as a noninvasive alternative to conventional screening methods like colonoscopy—which, despite clinical effectiveness, continue to face compliance challenges due to their invasive nature. Advances in multiomics—including proteomics, metabolomics, transcriptomics, and epigenomics—are enabling the identification of circulating biomarkers such as noncoding RNAs, DNA methylation signatures, disease-specific proteins, and metabolic profiles from plasma and serum samples. Emerging technologies like liquid biopsy, extracellular vesicle profiling, and machine learning–driven analytics are further…
In a bid to close persistent colorectal cancer (CRC) screening gaps, Guardant Health has launched a community grant program offering up to 100 free Shield blood-based screening tests per organization during Colorectal Cancer Awareness Month this March. FDA-approved for average-risk adults aged 45 and older, Shield uses methylation-based cfDNA analysis to detect colorectal cancer–associated alterations from a simple blood draw—potentially overcoming participation barriers tied to stool-based or invasive screening methods. The initiative is aimed at underserved and historically under-screened populations, enabling nonprofits and public health groups to host local screening drives and educational outreach events at no cost to patients.…